LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, announced that Europe’s leading gene therapy engineer of viral vectors, SIRION Biotech GmbH, has been added to its client roster.
LHS provides strategic communications programming and corporate development expertise to SIRION Biotech, helping to connect SIRION Biotech to relevant stakeholders in the U.S. life science ecosystem. This is particularly important as SIRION Biotech plans its expansion into the U.S. market with its new Cambridge, MA site beginning January 2019.
SIRION Biotech has been engaged in research and licensing collaborations with 3 leading U.S. biotechs in the gene therapy field since 2015. The earliest project was assisted by LaVoieHealthScience beginning in 2014, when the Germany based company with deep scientific roots in gene expression was seeking U.S. partnerships with clinical-stage gene therapy companies in order to expedite their R&D efforts. Partnering together, LaVoieHealthScience and SIRION Biotech built its U.S. profile, visibility and outreach efforts.
“Partnering with LaVoieHealthScience helped us unleash our potential as a business to business provider of custom engineered viral vectors for industrial and academic research and development,” said Chief Operating Officer and Executive Director, Dieter Lingelbach. “Our planned expansion into the U.S. market will be a strategic imperative for SIRION Biotech and we are delighted to continue working with LaVoieHealthScience as we chart our course forward.”
“We are fortunate to continue working with SIRION Biotech as Europe’s leader in the gene therapy field on its next stage of growth and continue our successful partnership together,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience.
Want more like this?
Subscribe to get daily or weekly PR News updates from Bulldog Reporter
More than 6 in 10 (61 percent) Americans are concerned about the products they put in, on and around their bodies—but a third (34 percent) say they rarely or never research product claims, new research from public health and safety org NSF International reveals. All...
In a world where positive reviews hold more value than paid ads and, thus, bring in more revenue, it's only logical that businesses would be going the extra mile in an attempt to encourage people to leave a positive review. How would you react if we were to tell you...
Most of us have heard the famous phrase, “It takes many good deeds to build a good reputation, and only one bad one to lose it.” Unfortunately, these days, you don't have complete control over your own reputation. There was a time when, as long as your company didn't...